DEF: Femasys Seeks Reverse Split to Maintain Nasdaq Listing

Femasys Inc. has called a special meeting for April 29, 2026, to seek shareholder approval for a reverse stock split and the issuance of shares related to convertible notes and warrants.

Summary

• The company is seeking approval for a reverse stock split at a ratio between 1-for-2 and 1-for-25 to regain compliance with Nasdaq's minimum bid price requirement.
• Shareholders are asked to approve the potential issuance of common stock upon conversion of senior secured convertible notes and exercise of warrants, specifically to address anti-dilution provisions that could trigger Nasdaq shareholder approval rules.
• The company has been granted a 180-day extension by Nasdaq until July 13, 2026, to regain compliance with the $1.00 minimum bid price rule.
• As of March 27, 2026, there were 60,390,686 shares of common stock outstanding.
• The board of directors has the discretion to determine the final ratio and whether to implement the reverse stock split at any time prior to May 1, 2027.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a defensive filing. While necessary for maintaining Nasdaq listing, the requirement for a reverse stock split and the potential for significant dilution from existing convertible instruments highlight the company's ongoing financial challenges.

Positives

• The reverse stock split is intended to increase the per-share trading price, potentially improving marketability to institutional investors.
• The proposal aims to ensure continued listing on the Nasdaq Capital Market, avoiding the liquidity risks associated with delisting.
• The company has secured a 180-day extension from Nasdaq to regain compliance, providing a clear timeline for corrective action.

Negatives

• The company is currently not in compliance with Nasdaq's minimum bid price rule, having traded below $1.00 for 30 consecutive business days.
• The stock price has declined from $0.58 on January 1, 2026, to $0.51 on March 25, 2026.
• The proposed actions, particularly the issuance of shares upon conversion of notes and warrants, will result in dilution to existing shareholders.

Risks

• There is no guarantee that a reverse stock split will result in a sustained increase in the stock price or satisfy Nasdaq requirements.
• The company may need to raise additional equity capital to fund operations, which could further dilute existing shareholders.
• If the company fails to regain compliance with the minimum bid price requirement by July 13, 2026, its common stock will be subject to delisting.
• The reverse stock split could lead to increased price volatility or a decline in the market price due to the perception of financial distress.
• The company's ability to raise capital may be adversely affected by a declining market price.

Future Outlook

The company intends to use the reverse stock split to regain Nasdaq compliance and potentially attract a broader range of institutional investors. It also plans to utilize the authorized but unissued shares to raise necessary equity capital to fund operations.

Management Comments

• The board of directors believes that the reverse stock split will likely result in a higher per share trading price, generating greater investor interest.
• The company believes that the current market price of its common stock may affect its acceptability to certain professional investors.
• The board of directors believes it is in the best interests of the company and its stockholders to grant the authority for the reverse stock split.

Industry Context

StockSavvy.ai notes that Femasys is following a common playbook for micro-cap biotech companies struggling with Nasdaq compliance. The combination of a reverse stock split and the need for shareholder approval for potential dilutive issuances is a standard, albeit often negative, signal of ongoing capital constraints and the need to maintain exchange listing status to facilitate future financing.

Comparison to Industry Standards

• The use of a reverse stock split to maintain Nasdaq listing is a standard practice for companies with share prices consistently below $1.00.
• The reliance on convertible notes and warrants with anti-dilution provisions is common in the biotech sector for companies with limited cash flow.
• The 1-for-2 to 1-for-25 ratio range is consistent with market norms for companies attempting to boost share price to meet exchange requirements.

Corporate Governance

Related Party Transactions

• Certain directors and officers of the company participated in the November 2025 private placement and purchased notes and warrants on the same terms as other investors.

Stakeholder Impact

• Existing shareholders face potential dilution from the conversion of notes and exercise of warrants.
• Shareholders will experience a reduction in the number of shares held following the reverse stock split, though proportional ownership remains unchanged.
• The company's ability to maintain its Nasdaq listing is critical for liquidity and investor access.

Next Steps

• Hold the Special Meeting of Stockholders on April 29, 2026.
• Tabulate votes for the three proposals.
• File a Form 8-K with the SEC within four business days after the meeting to announce the voting results.
• If approved, the board may determine the final ratio and file a Certificate of Amendment to the Certificate of Incorporation.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by the need for a reverse stock split to maintain its Nasdaq listing and the reliance on dilutive financing. While the proposals are necessary for survival, they do not signal growth or fundamental improvement, suggesting a cautious 'hold' for existing investors until the company demonstrates a path to sustainable operations.

Keywords

Femasys, FEMY, Reverse Stock Split, Nasdaq Delisting, Proxy Statement, Convertible Notes, Shareholder Meeting, Equity Financing